Cytokinetics (CYTK), Amgen (AMGN) to Advance Omecamtiv Mecarbil to Phase 3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Wall St set for higher open as upbeat earnings obscure Mideast jitters
- UnitedHealth to take up to $1.6 billion hit from Change Healthcare hack this year
- Morgan Stanley's profit beats as investment banking rebounds
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Stocks sag, dollar up as 'higher for longer' rate view takes root
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Needham & Company Positive on Cytokinetics (CYTK) as Amgen to Move Ahead with Omecamtiv Phase III
September 1, 2016 12:45 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $17 price target on Cytokinetics (NASDAQ: CYTK) after Amgen (NASDAQ: AMGN) made its long awaited decision to move forward with a Phase III study for omecamtiv in heart failure.... More
Amgen (AMGN) Announces Servier Decision to Exercise Option on Omecamtiv Mecarbi
September 1, 2016 8:38 AM EDTAmgen (Nasdaq: AMGN) and Servier announced an advancement in their cardiovascular collaboration, with Servier's decision to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia, which were added to the collaboration. The companies also announced the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics.
Under the terms of the agreement, Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments, to Amgen. Servier will assume a... More
